PLAQUE PSORIASIS

This study tested a gel called SGX302 (synthetic hypericin) combined with visible light to treat mild-to-moderate psoriasis. Fifteen adults with plaque psoriasis applied the gel to their skin and received light therapy over 18 weeks. The goal was to see if the treatment could cle…

This study tested a new daily pill, ESK-001, in 862 adults with moderate to severe plaque psoriasis. The goal was to see if it reduces skin severity and is safe, comparing it to a placebo and an existing drug (apremilast). Participants took the pill for 24 weeks and had regular c…

This study tested the drug guselkumab in 213 adults with skin of color who have moderate-to-severe plaque or scalp psoriasis. Participants received either the drug or a placebo for 16 weeks. The main goal was to see if guselkumab could clear at least 90% of psoriasis patches on t…

This study tested an experimental drug called TQH3906 in 209 adults with moderate to severe plaque psoriasis. The main goal was to see how well it cleared skin symptoms after 12 weeks of treatment. Researchers also checked for side effects and how the drug moved through the body.

This study looked at how well and how safely a biosimilar drug called QLETLI (similar to adalimumab) works for children and teenagers aged 4 to 17 with severe plaque psoriasis. A total of 80 participants received the drug and were followed for 24 weeks. The main goal was to see i…

This study tested an experimental drug called JNJ-77242113 in 255 adults with moderate-to-severe plaque psoriasis. Participants took different doses of the drug or a placebo for 16 weeks. The main goal was to see if the drug could clear at least 75% of psoriasis patches. This is …

This study tested an experimental pill called D-2570 in 161 adults with moderate-to-severe plaque psoriasis. Participants took the pill or a placebo daily for 12 weeks. The main goal was to see if the pill could clear at least 75% of skin plaques. Results are being analyzed to de…

This study tested a new drug, netakimab, in 202 Chinese adults with moderate to severe plaque psoriasis. Participants received either netakimab or a placebo to see if the drug could improve skin symptoms. The main goal was to measure at least a 75% improvement in psoriasis severi…

This study tested a new medication called TAK-279 for people with moderate-to-severe plaque psoriasis, a skin condition that causes red, scaly patches. About 693 adults took either TAK-279, an approved drug (apremilast), or a placebo for up to 61 weeks. The goal was to see if TAK…

This study looked at whether bimekizumab can safely and effectively treat moderate-to-severe plaque psoriasis in adults who did not get better with similar drugs (IL-17 or IL-23 blockers). Bimekizumab works by reducing inflammation in the body. The goal was to see if it could cle…

This study tested a new oral medication, JNJ-77242113, in 227 adults with moderate-to-severe plaque psoriasis who had already completed a previous 16-week study. The goal was to see how well the drug worked over 36 weeks, measuring skin improvement using the Psoriasis Area Severi…

This study tested a higher dose (10 mg/kg every 8 weeks) of the drug TA-650 in 51 adults with psoriasis whose symptoms had returned after initially responding to the standard dose of Remicade. The goal was to see if the increased dose could again improve skin symptoms, as measure…

This study tested whether a new daily pill, zasocitinib, works better than another pill, deucravacitinib, for people with moderate-to-severe plaque psoriasis. Over 600 adults took one of the two treatments daily for 16 weeks. The main goal was to see how many people achieved comp…

This observational study followed 331 adults with moderate to severe plaque psoriasis who were treated with tildrakizumab (Ilumetri) in routine medical practice. Researchers measured how much the skin cleared up and how quality of life improved over 48 to 100 weeks. The goal was …

This study tested an experimental oral tablet (JNJ-77242113) against a placebo in 90 adults with moderate-to-severe plaque psoriasis. The main goal was to see if the pill could reduce psoriasis severity by at least 75% after 16 weeks. Participants had to have psoriasis for at lea…

This study tested an experimental oral drug, TAK-279, in over 1,100 adults with moderate-to-severe plaque psoriasis. Participants received either TAK-279, an approved psoriasis medication (apremilast), or a placebo for up to 69 weeks. The main goal was to see if TAK-279 could cle…

This study tested a daily pill called apremilast in 203 Chinese adults with moderate to severe plaque psoriasis. Participants took either the drug or a placebo for 16 weeks. The main goal was to see if the drug could reduce psoriasis severity by at least 75% compared to no treatm…

This study tested an experimental drug called LY4100511 in 222 adults with moderate-to-severe plaque psoriasis. Participants stopped other psoriasis treatments and received either the drug or a placebo. The main goal was to see how well the drug cleared skin and if it was safe. R…

This study looked at whether an artificial intelligence (AI) tool can help primary care doctors diagnose skin conditions more accurately. Nine doctors reviewed 30 skin images, first giving a diagnosis on their own, then with AI suggestions. The goal was to see if the AI improved …

This study tested an experimental oral drug, LY3972406, in 33 adults with moderate-to-severe plaque psoriasis. The goal was to see if it safely reduces skin symptoms like redness, thickness, and scaling. Participants were randomly assigned to receive the drug or a placebo, and re…

This study tested a cream called tapinarof on 575 adults with mild-to-moderate plaque psoriasis. The goal was to see if it safely clears skin patches better than a placebo cream. Participants used the cream daily for several weeks, and doctors checked for improvement.

This study tested a new drug called AX-158 in 31 adults with mild to moderate plaque psoriasis. Participants took either the drug or a placebo daily for 28 days, then were monitored for another 30 days. The main goal was to check safety and side effects, with some early looks at …

This study involved 291 adults with mild-to-moderate scalp psoriasis who used a prescription cream (CAL/BDP PAD cream). Researchers measured how satisfied patients were with the treatment, its effect on their quality of life, and how well it worked in real-world settings. The goa…

This study tested a new daily pill, ESK-001, in 912 adults with moderate to severe plaque psoriasis. Participants took the drug, a placebo, or an approved psoriasis medicine for 24 weeks. The goal was to see if ESK-001 safely reduces psoriasis severity and improves quality of lif…

This study involved 324 adults with conditions like Crohn's disease, arthritis, or psoriasis who switched from a standard to a higher-concentration adalimumab injection. Researchers measured injection site pain and how well patients stuck with the new treatment over 180 days. The…

This study tested a new drug, CAN10, for the first time in humans. It aimed to see if the drug is safe and how the body handles it. The trial included 80 healthy adults and people with mild to moderate plaque psoriasis. The drug was given as a single dose to healthy volunteers an…

This study checked whether digital photographs can reliably measure psoriasis severity compared to in-person doctor evaluations. Thirty-four adults with plaque psoriasis had their skin scored both in person and from photos. The goal was to see if remote scoring could be a trustwo…

This study tested whether an artificial intelligence (AI) tool could help doctors more accurately diagnose rare and tricky skin conditions like generalized pustular psoriasis. Fifteen general practitioners and dermatologists reviewed 100 skin images, first giving their own diagno…